ClinicalTrials.Veeva

Menu

Initiative to Minimize Disparities in Postoperative Prostate Cancer Care

A

Albert Einstein Healthcare Network

Status

Terminated

Conditions

Post Prostatectomy

Treatments

Other: Absorbent pad for urinary incontinence

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Einstein Healthcare Network in North Philadelphia serves a predominantly underserved medical community. The investigators routinely see patients who cannot afford absorbent pads after prostate surgery, which helps with quality of life secondary to urinary incontinence. The investigators will provide absorbent pads to participants who would be unable to afford them. The investigators hypothesize that providing absorbent pads for 6 months will result in improved quality of life in regards to management of urinary incontinence after radical prostatectomy.

Full description

When detected early and managed with appropriate surgical treatment, such as radical prostatectomy, Prostate cancer prognosis is excellent, but recovery may be associated with significant transient impact on quality of life. This impact most often manifests in urinary domains, specifically, development of stress urinary incontinence. Several simple, low-cost but high-yield interventions may dramatically improve patient's postoperative quality of life. However, such interventions may be out of reach for patients from Health Enterprise Zones (HEZ) with limited funds. To make resources readily available for this patient population, the inclusion criteria will be prostatectomy patients of any age who reside within the designated North Broad street HEZ.

Stress urinary incontinence after prostatectomy is a source of major distress. Incontinence tends to improve over time with most patients regaining their urinary function. Symptomatic support with disposable absorbent pads/diapers for several months helps men effectively manage this side effect. While for most men the cost of the diapers is manageable, for men in HEZ this represents a significant financial burden on the patient and on caregivers. As a result, these patients often choose to remain home bound until they recover urinary control, preventing them from early return to employment and resulting in social isolation. The Healthcare Disparity SEED Grant will provide up to a 6-month supply of disposable absorbent pads/diapers to those patients meeting our inclusion criteria. Michigan Incontinence Symptom Index (M-ISI) questionnaires will be distributed to patients pre-operatively and during interval post-operative office visits to assess patient satisfaction with voiding function.

In addition to distributing M-ISI questionnaires, we will also distribute the Extended Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) to evaluate overall quality of life. This is a validated questionnaire capable of accurately assessing multiple domains of quality of life after prostate cancer treatment. Results of M-ISI and EPIC-CP scores will be compiled and analyzed to determine if intervention has resulted in measurable improvement between the treatment and control groups.

Enrollment

24 patients

Sex

Male

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  1. History of prostate cancer
  2. Scheduled for radical prostatectomy during a designated academic year
  3. Reside within Health Enterprise Zone (HEZ) of North Broad Street
  4. Median annual household income < $50,000
  5. Patient feels that they would struggle to afford absorbent pads and Tadalafil based on their annual income
  6. Patient must have no history of stress urinary incontinence prior to surgery

Exclusion Criteria

  1. Patient's who do not meet the inclusion criteria above
  2. Patients who meet all inclusion criteria above, but do not want to use absorbent pads secondary to history of hypersensitivity/allergy to absorbent pads
  3. Patients with cognitive impairment will be excluded from the study

Trial design

24 participants in 2 patient groups

Group 1 (Provided absorbent pads)
Description:
Patients will receive a 6 month supply (as needed) of absorbent pads for urinary incontinence.
Treatment:
Other: Absorbent pad for urinary incontinence
Group 2 (not provided absorbent pads)
Description:
Patients enrolled in the control arm will not receive absorbent pads.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems